Vitreous prostaglandin e2 changes after topical administration of diclofenac 0.1%, indomethacin 0.5%, nepafenac 0.3%, and bromfenac 0.09%

Purpose: To evaluate the vitreous concentration of different nonsteroidal anti-inflammatory drugs (NSAIDs) after topical administration and the related prostaglandin E2 (PGE2) levels in patients undergoing pars plana vitrectomy. Methods: A prospective, randomized, investigator-masked study was performed. One hundred four patients scheduled for a pars plana vitrectomy for an epiretinal membrane or a macular hole were randomized to receive topical diclofenac 0.1%, indomethacin 0.5%, nepafenac 0.3%, bromfenac 0.09%, or placebo 3 days before surgery. At the beginning of surgery, a sample of undiluted vitreous was collected in each patient to assess NSAIDs concentration and PGE2 levels. Results: The median vitreous concentrations were 203.35 (interquartile range 146.54–264.18) pg/mL for diclofenac, 243.45 (interquartile range 156.96–365.37) pg/mL for nepafenac, 438.21 pg/mL (interquartile range, 282.52–645.87) for its active metabolite amfenac, 350.14 (interquartile range, 290.88–481.95) pg/mL for indomethacin, and 274.59 (245.43–358.25) pg/mL for bromfenac. Vitreous PGE2 levels were significantly lower for all the NSAIDs groups compared with the control group (P
Source: RETINA - Category: Opthalmology Tags: Original Study Source Type: research